DALLAS, Nov. 27, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Puration, Inc. (USOTC: PURA) today confirmed its $4 million 2019 revenue target and plans for reaching $8 million in 2020 in light of the most recent financial report for the period ended September 30, 2019.
PURA reported $1,895,000 in revenue year-to-date through the period ending September 30, 2019. The year-to-date revenue reflects over one hundred percent (100%) growth. The company also realized a twelve (12%) percent increase in net profit to $232,500 for the same period.
Were sales to remain relatively steady from Q3 to Q4, the 2019 annual income would come in at approximately $2.7 million. To reach the $4 million 2019 revenue target will require an additional approximate $1.3 million in sales. With major distribution agreements recently signed in Europe and Latin America that include initial shipments currently in progress, management indicates that the $4 million target remains within reach. The potential of reaching the $4 million sales target is bolstered by the company’s recent introduction of TranquiliTea CBD adding to its existing EVERx CBD Sports Water. Being on pace to exceed 100% revenue growth is an achievement in and of itself aside from the $4 million revenue target. Management believes the 2020 $8 million revenue target remains an achievable goal and one that can be potentially substantially surpassed. Management is pleased with the company’s growth to date and continuing growth potential.
For more information on Puration, visit http://www.purationinc.com.
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350